Background: ATP-binding cassette transporters (ABCA1, ABCG1) and scavenger receptor class B type I (SR-BI) are the three most important cellular cholesterol transporters/receptor in regulating cholesterol efflux. We have investigated whether the expression of these transporters/receptor is altered in overweight and obese patients, and the potential association with the circulating adipokines. Methods: Adiponectin, leptin and resistin were assayed in two groups of healthy controls, overweight and obese patients. The expression of ABCA1, ABCG1 and SR-BI in monocytes was measured. Cholesterol efflux from monocyte-derived macrophages was also determined. Results: Circulating adiponectin was decreased, whereas leptin and resistin were increased in overweight and obese patients compared with healthy controls. ABCA1 expression was significantly decreased in overweight and obese patients (Po0.01), whereas the levels of ABCG1 and SR-BI were comparable between the two groups. Adiponectin was correlated with ABCA1 (r ¼ 0.44, Po0.001), but not with ABCG1 and SR-BI. No associations between leptin, resistin and the expression of ABCA1, ABCG1 and SR-BI were found. Cholesterol efflux from monocyte-derived macrophages to apolipoprotein AI or to autologous serum was significantly impaired in overweight and obese patients, which were correlated with ABCA1 expression (r ¼ 0.47, Po0.001; r ¼ 0.43, Po0.001, respectively). Conclusion: The expression of ABCA1 in monocytes is reduced in overweight and obese patients, and the reduction in ABCA1 is associated with the impairment of cholesterol efflux from monocyte-derived macrophages.
Introduction
Reverse cholesterol transport (RCT) is a pathway that transports cholesterol from extrahepatic cells and tissues to the liver for excretion, and cholesterol efflux is the first critical step of RCT. 1 Specifically, cholesterol efflux from macrophages represents only a small fraction of overall cellular cholesterol efflux, but it is probably the most important with regard to atherosclerosis, and it has recently been termed macrophage RCT, as excess lipid accumulation within macrophages in peripheral artery wall may lead to foam cell formation. 1 ATP-binding cassette transporters (ABCA1, ABCG1) and scavenger receptor class B type I (SR-BI) are the three best characterized cellular transporters/ receptor that are involved in mediating macrophage cholesterol efflux in animal models and in vitro experiments. [2] [3] It is widely considered that ABCA1 mediates cholesterol efflux from macrophages to lipid-free apolipoprotein AI (apoAI), whereas ABCG1 mediates macrophage cholesterol efflux to mature high-density lipoprotein (HDL) in vitro. SR-BI is expressed in hepatocytes and macrophages and also mediates cholesterol efflux to mature HDL in vitro. Studies in knockout mice have recently shown that cholesterol efflux from mouse macrophages in vivo is mainly mediated by ABCA1 and ABCG1, but not by SR-BI. 4 However, limited data in humans have been obtained. Obesity is associated with the increased risk of cardiovascular diseases (CVD). It has been found that HDL maturation may be abnormal that prebHDL is higher, but mature HDL is decreased in obese patients, 5 which may influence cholesterol transport between cells and HDL. 6 Weight reduction appears to reverse these abnormalities in HDL maturation. 7 Low circulating adiponectin, which is one of the important metabolically active cytokines secreted from adipocytes, has been associated epidemiologically with obesity and CVD. It has been revealed that plasma HDL cholesterol is positively correlated with adiponectin concentrations in humans. 8 Adiponectin may protect against atherosclerosis by increasing HDL assembly through enhancing ABCA1-mediated cholesterol efflux and apoAI synthesis in the liver. [9] [10] Concerning macrophage RCT, in vitro experiments have shown that adiponectin can upregulate the expression of ABCA1 and cholesterol efflux from human macrophages. [11] [12] In adiponectin knockout mice, the expression of ABCA1 and cholesterol efflux from macrophages is decreased compared with wild-type mice. 12 However, whether adiponectin may influence ABCG1 and SR-BI is unclear, and few studies about the effects of adiponectin on cholesterol efflux from macrophages in humans have been carried out.
Other than adiponectin, resistin and leptin are also important adipokines through which obesity is associated with the increasing prevalence of CVD. In contrast to adiponectin, high resistin and leptin are associated with the risk of CVD, through the mechanisms such as stimulating vascular inflammation. [13] [14] Resistin may enhance macrophage cholesteryl ester deposition and contribute to macrophage foam cell formation. 15 It has been reported that leptin may decrease ABCA1 expression in human monocytederived macrophages. 16 Whether resistin and leptin are involved in macrophage RCT in humans remains to be determined. The aims of this study were, therefore, to determine the expression of ABCA1, ABCG1 and SR-BI in peripheral monocytes in overweight and obese patients and to investigate whether the alteration of these cellular cholesterol transporters/receptor might influence cholesterol efflux from monocyte-derived macrophages ex vivo.
Methods
Forty overweight and obese patients, and 20 age-, gendermatched healthy controls were recruited according to Chinese body mass index (BMI) criterion: BMI of 18.5-23.9 is considered as normal, and X24 as overweight and obese 17 during their annual examination. Healthy controls, overweight and obese patients were confirmed to have no known diseases (including diabetes, CVD, thyroid diseases, hypertension, abnormal liver or renal function, any other acute and chronic disease conditions or any current infectious condition). We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research. The study was approved by the ethics committee of College of Medicine, Zhejiang University, China, and informed consent was obtained from each subject.
Age, gender, weight, height, waist, blood pressure, history of smoking and medications were recorded. BMI was calculated as weight (kg) per square height (m 2 ). Mean blood pressure was calculated as diastolic pressure þ 1/3 Â (systolic pressureÀdiastolic pressure). Blood samples were taken after an overnight fast. The samples were centrifuged, plasma and serum were aliquoted and immediately frozen at À80 1C. Total cholesterol, low-density lipoprotein (LDL) cholesterol, HDL cholesterol and triglyceride were determined on HITACH 7170 biochemical autoanalyzer. Plasma prebHDL level was determined by crossed immunoelectrophoresis as previously described by Hattori et al. 18 The levels of adiponectin, resistin and leptin were measured by commercially available kits according to the instructions of the manufacturers. Plasma adiponectin was measured by enzyme-linked immunosorbent assay (ELISA; B-Bridge International, Phoenix, AZ, USA). Plasma resistin was also measured by ELISA (BioVendor Laboratory Medicine, Candler, NC, USA). Serum leptin was measured by RIA (Linco Research, St Charles, MO, USA) Peripheral blood monocytes were isolated as previously described by Zhou et al. 19 Briefly, 40 ml of fasting blood was collected from each subject using 4 ml 3.8% sodium citrate as anticoagulant. Blood sample was layered carefully on FicollPaque solution (Amersham Biosciences, Piscataway, NJ, USA), and centrifuged at 400 g for 30 min at 18-20 1C.
Mononuclear cells at the interface were collected, washed with sterile phosphate-buffered saline (PBS) and then resuspended with RPMI-1640 culture medium (Gibco, Grand Island, NY, USA). The mononuclear cells in the medium were added to culture plates and incubated in a cell culture incubator for 2-3 h. Unattached lymphocytes were removed gently. Attached monocytes were collected for cholesterol efflux assay immediately or stored at À70 1C for RNA extraction.
Cholesterol efflux from monocyte-derived macrophages was evaluated as the functional effects of the three cellular transporters/receptor according to Zhou et al. 19 with slight modification. The attached monocytes were differentiated into macrophages ex vivo by incubating in RPMI-1640 medium containing 10% autologous serum for 6 days according to Gianturco et al. 20 Then cellular cholesterol was labeled with tracer [ , or apoAI (Biodesign, Saco, ME, USA) 20 mg ml À1 or 5% autologous serum was then used to induce cholesterol efflux from the labeled cells for 4 h. Cholesterol efflux, expressed as percentage, was calculated as scintillation counting in the medium divided by the total counting of the medium and cells in each well. Total RNA was extracted, and cDNA was synthesized routinely. Commercial primer/probe sets for target genes ABCA1 expression in obesity M Xu et al ABCA1 (Hs00194045_m1), ABCG1 (Hs00245154_m1) and SR-BI (Hs00194092_m1) were used, and GAPDH was used as endogenous reference gene. PCR was performed in 96-well plates using 50 ng cDNA mixed with primers, probes and TaqMan Universal PCR Master Mix in a total volume of 50 ml in an ABI Prism 3730XL DNA Sequenator. All cDNA samples were assayed in triplicate. A reference cDNA sample was assayed in each experiment. The expression of the target gene was then expressed as the folds of the reference sample. ABCA1 protein in monocytes was measured by fluorescence-activated cell sorting (FACS) assay. Anti-human CD14 (eBioscience, San Diego, CA, USA) was used to label monocytes, and rabbit polyclonal anti-ABCA1 (Novus Biologicals, Inc., Littleton, CO, USA) was used to recognize ABCA1. Fasting blood (2 ml) was collected from each subject using ethylenediaminetetraacetic acid as anticoagulant. Blood sample was layered carefully on Ficoll-Paque solution, and centrifuged at 400 g for 30 min at 18-20 1C. Mononuclear cells at the interface were collected, washed with PBS and then resuspended in 120 ml FACS buffer containing the two antibodies (2.08 mg ml À1 of anti-CD14 and 6.25 mg ml Numerical data were expressed as mean and standard deviation. Logarithmical transformation was made if data were not normally distributed. Comparisons between the two groups were carried out using student t-test or w 2 -test. Pearson's correlations were used to test the associations between two variables, and linear regression model was used to assess the relationships between the expression of ABCA1, ABCG1 and SR-BI and various variables simultaneously. P-valueo0.05 was considered as statistically significant.
Results
The general characteristics, lipid profile and the three adipokines of the subjects are shown in Table 1 . There was no significant difference in age, gender and the proportion of smokers between the two groups. As expected, BMI was significantly higher in overweight and obese patients compared with healthy controls. The blood pressure was within normal range, and it was higher in overweight and obese patients compared with healthy controls. The plasma level of HDL was significantly lower, whereas LDL, triglycerides and prebHDL were higher in overweight and obese patients compared with healthy controls. Plasma adiponectin was also significantly decreased, whereas resistin and leptin were significantly increased in overweight and obese patients compared with healthy controls.
Peripheral circulating monocytes mainly expressed ABCA1 and ABCG1, and the expression of SR-BI was relatively low (Figure 1a ). There was a significant reduction in the mRNA level of ABCA1 in overweight and obese patients compared with healthy controls. The reduction of ABCA1 in overweight and obese patients remained significant after adjusting for age, gender, smoking and blood pressure. In contrast, the levels of ABCG1 and SR-BI were comparable between the two groups ( Figure 1a ). Because ABCA1 mRNA was decreased in overweight and obese patients, we further measured ABCA1 protein in monocytes and found that ABCA1 expression was also decreased in overweight and obese patients at protein level (Figure 1b) . 
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Circulating adiponectin was significantly correlated with the expression of ABCA1 (r ¼ 0.44, Po0.001), but not with that of ABCG1 and SR-BI ( Table 2 ). The association between adiponectin and ABCA1 expression remained significant after adjusting for potential confounding factors such as age, gender, smoking and blood pressure ( Table 3 ), suggesting that the reduction of ABCA1 expression in obese patients might be partly due to lower adiponectin level. No associations between circulating leptin, resistin and the expression of ABCA1, ABCG1 and SR-BI were found (Table 2) .
To determine whether the reduction of ABCA1 expression in overweight and obese patients might have a functional effect, we measured cholesterol efflux from monocyte-derived macrophages. Cholesterol efflux from monocyte-derived macrophages to apoAI was decreased in overweight and obese patients compared with healthy controls (Figure 2 ), but cholesterol efflux from monocytederived macrophages to HDL was comparable between the two groups. When similar experiments were repeated using autologous serum as cholesterol acceptor, cholesterol efflux from monocyte-derived macrophages was also decreased in overweight and obese patients (Figure 2) .
On correlation analysis, we found that ABCA1 expression was significantly associated with cholesterol efflux from monocyte-derived macrophages to apoAI (Figure 3a) or that to autologous serum (Figure 3b ), but not with that to HDL. No significant associations between the expression of ABCG1, SR-BI and cholesterol efflux from monocyte-derived macrophages to various cholesterol acceptors were found. Pearson's correlation coefficients are shown. *Po0.001. ABCG1, ABCA1 and SR-BI mRNA were logarithmically transformed before analysis. ABCA1 expression in obesity M Xu et al Discussion ABCA1, ABCG1 and SR-BI are important in regulating macrophage cholesterol efflux and reducing the accumulation of lipids in arterial wall, whereby they may prevent the development of atherosclerosis. This is the first study to examine the expression of the three major cholesterol transporters/receptor, ABCA1, ABCG1 and SR-BI, in overweight and obese condition. We have found that among the three cellular cholesterol transporters in our patients, ABCG1 expression was the most abundant, followed by ABCA1 whereas the level of SR-BI expression was relatively low, which is consistent with the previous findings in type II diabetic patients. 19 We have clearly shown that the expression of ABCA1 was significantly reduced in overweight and obese patients, whereas the level of ABCG1 or SR-BI was similar to that in healthy controls. Furthermore, we also found that the reduction of ABCA1 in overweight and obese patients was related to lower circulating level of the antiatherogenic adipokine adiponectin, but not associated with higher levels of the proatherogenic adipokines leptin and resistin. This is in keeping with data from in vitro experiments and animal studies showing that adiponectin can upregulate ABCA1 expression and cholesterol efflux from macrophages, [11] [12] and knockout adiponectin can decrease the expression of ABCA1.
12
The activation of peroxisome proliferator-activated receptor g (PPARg) and liver X receptor a (LXRa) is the major mechanism through which macrophage ABCA1 and ABCG1 expression can be upregulated. 2 In vitro experiments and animal studies have suggested that adiponectin can increase apoAI-mediated cholesterol efflux from macrophages through ABCA1-dependent pathway by the activation of PPARg and LXRa. 12 Our present study has added in vivo evidence that ABCA1 expression in overweight and obese patients is altered and it is related to the reduction of adiponectin. Whether the in vivo modulation of ABCA1 by adiponectin in our patients may be through the similar mechanism of PPARg/LXRa pathway remains to be confirmed. Interestingly, ABCA1 and ABCG1 both belong to the superfamily of ABC transporters. ABCA1 is a full ABC transporter, whereas ABCG1 is half transporter, 2 and they may share similar mechanisms of regulation. However, it has also been evidenced that the regulation of ABCA1 and ABCG1 expression might be different through LXR-independent pathway. [21] [22] In present study, we also found that the reduction in circulating adiponectin resulted in the lower expression of ABCA1, but not that of ABCG1. Demonstrating the underlying mechanisms through which the two important cholesterol transporters are differently regulated in overweight and obese condition may lead to a better understanding of their functions in regulating cholesterol efflux and macrophage RCT.
We have chosen to use pure particles of apoAI as cholesterol acceptors to measure ABCA1-mediated cholesterol efflux, and HDL to measure ABCG1-or SR-BI-mediated cholesterol efflux from monocyte-derived macrophages. Consistent with the alteration of gene expression, the reduction in ABCA1 expression in overweight and obese patients was associated with a reduction in cholesterol efflux from monocytederived macrophage to apoAI. However, cholesterol efflux from monocyte-derived macrophage to HDL was comparable between healthy controls, overweight and obese patients, which might be at least partially due to the preservation of ABCG1 and SR-BI expression in the overweight and obese patients. We also used autologous serum to induce cholesterol efflux from monocyte-derived macrophages to mimic in vivo situation. Cholesterol efflux from monocyte-derived macrophages to autologous serum was also significantly decreased in overweight and obese patients, and it was associated with the level of ABCA1 expression, but not that of ABCG1 or SR-BI. These findings suggested that the reduction of ABCA1 might lead to the impairment of cholesterol efflux, the first step of RCT in the overweight and obese patients.
There are several limitations in this study. We could only measure the expression of ABCA1, ABCG1 and SR-BI in peripheral blood monocytes, which are easily accessible. The measurements in macrophages in the arterial wall of patients are not feasible. mRNA expression of these transporters/ receptor was determined in freshly isolated blood monocytes to determine their basal level in vivo, as ABCA1, ABCG1 and SR-BI might be altered during the differentiation of monocytes to macrophages in vitro. [23] [24] [25] In our preliminary experiments, protein expression of ABCA1, ABCG1 and SR-BI could hardly be detected by western blot. We only measured ABCA1 protein by FACS assay, and no suitable antibodies for ABCG1 and SR-BI were available. We have demonstrated associations of ABCA1 expression in monocytes with plasma adiponectin and with cholesterol efflux from monocyte-derived macrophages, but whether they are causal relationships or not need further investigation. The effect of weight loss on the expression of ABCA1, ABCG1 and SR-BI in overweight and obese patients also warrants future clarification. In conclusion, the expression of ABCA1 in peripheral monocytes is reduced in overweight and obese patients, which may be partly due to the lower circulating adiponectin. The reduction in ABCA1 expression is associated with the impairment in cholesterol efflux from monocyte-derived macrophages, which may potentially accelerate the foam cell formation and atherogenesis in these patients.
